Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia
Immune Thrombocytopenia
Enrolment: 15 · Results not recorded
Loading the evidence…
Biologic · AGONIST at the thrombopoietin receptor (MPL/TPOR); direct interaction, disease efficacy true. ATC B02BX04. Peptibody (Fc-peptide fusion), parenteral.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Immune Thrombocytopenia
Enrolment: 15 · Results not recorded
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia
Enrolment: 234 · Results not recorded
Chemotherapy-induced Thrombocytopenia
Enrolment: 0 · Results not recorded
MDS · Myelodysplastic Syndromes · Thrombocytopenia
Enrolment: 250 · Results not recorded
Multiple Myeloma · Thrombocytopenia
Enrolment: 5 · Results not recorded
Aplastic Anemia
Enrolment: 43 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Lethal-dose whole-body ionising radiation exposure
Romiplostim administration after lethal-dose irradiation promoted haematopoiesis in multiple organs, reduced organ and cell damage, rapidly increased splenic mesenchymal stem cell number and suppressed several miRNAs involved in radiation-induced leukemogenesis.
Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.
Model: Lethal total-body X-irradiation at 7, 7.25 or 7.5 Gy
The clinical-dose G-CSF and romiplostim combination improved 30-day survival after lethal total-body irradiation and reduced haematopoietic apoptosis and oxidative stress.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.